Background In patients with ischemic stroke of non-cardioembolic origin, acetylsalicylic acid,
clopidogrel, or a combination of acetylsalicylic acid and dipyridamole are recommended for …

Patients with transient ischemic attack (TIA) or ischemic stroke carry a risk of recurrent stroke
of between 5% and 20% per year. In patients with TIA or ischemic stroke of non-cardiac …

Background The current guidelines recommend various antiplatelet agents used alone or in
combination for secondary prevention of noncardioembolic stroke. Objective The purpose of …

Opinion statement Antiplatelet medications are the agents of choice for secondary
prevention of noncardioembolic ischemic strokes. Multiple clinical trials have proven their …

Background Clopidogrel was thought to be superior to aspirin for secondary prevention of
vascular diseases in clinical trials. In this study we assessed the safety and efficacy of …

Objectives Despite large clinical trials, there is no consensus about the best antithrombotic
strategy for the secondary prevention of non-cardioembolic ischaemic stroke. This …

Antiplatelet drugs have an established efficacy in the secondary prevention of ischemic
stroke. The recent results of the CAPRIE, CURE, and CREDO studies formed the rationale …

Background Several clinical trials reported that clopidogrel was superior to aspirin in
secondary stroke prevention by reducing the risk of major adverse cardiovascular events …

Background In real-world practice settings, there is insufficient evidence on the efficacy of
antiplatelet drugs, including clopidogrel, aspirin, and ticlopidine, in stroke prevention …

Background and Purpose Antiplatelet therapy is widely used for the primary or secondary
prevention of stroke. Drugs like clopidogrel have emerged as alternatives for traditional …